You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
輝瑞新冠藥物療效顯著 港股抗議概念股普跌 開拓藥業(9939.HK)跌8%
格隆匯11月8日丨因輝瑞宣佈新冠口服藥療效顯著,上週五美股抗疫概念股集體收跌,拖累今早港股市場抗疫概念股普遍低開。其中,騰盛博藥跌超11%,開拓藥業跌8%,康希諾跌近7%,復星醫藥跌超3%。上週五,輝瑞宣佈其新冠口服藥物Paxlovid減少新冠肺炎非住院患者的住院或死亡率高達89%。治療組住院或死亡率為0.8%(389例中3例住院,無死亡),安慰劑組住院或死亡率為7%(385例中27例住院,其中7例隨後死亡)。這一數據媲美甚至好於新冠中和抗體,顯著優於默沙東的Molnupiravir。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.